|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Avenanthramide A Induces Cellular Senescence via miR-129-3p/Pirh2/p53 Signaling Pathway To Suppress Colon Cancer Growth.
|
30888162 |
2019 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Avenanthramide A Induces Cellular Senescence via miR-129-3p/Pirh2/p53 Signaling Pathway To Suppress Colon Cancer Growth.
|
30888162 |
2019 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to highlight the role of p53-induced RING-H2 (Pirh2) in the acquisition of bortezomib resistance in MM and to clarify the function and mechanism of action of Pirh2 in MM cell growth and resistance, thereby providing the basis for new therapeutic targets for MM.
|
29441489 |
2018 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Several novel findings were obtained: (i) cytoplasmic p27 was observed in 8.6%, most frequently in SCC (13.3%), and correlated with nodal metastasis (P=.0044), (ii) significant inverse correlation between nuclear p27 and Pirh2 expression was observed by statistical analysis and at the cellular level, and (iii) cytoplasmic Pirh2 and total (cytoplasmic and/or nuclear) Pirh2 were significantly correlated with the nodal status (P=.0225, 0.0314), the pathological stage (P=.0213, 0.0475) and recurrence-free survival (P=.0194, 0.0482, respectively) in AC.
|
28601655 |
2017 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Altogether, our data suggests that p27 and its cognate ubiquitin ligases are specifically involved in the clinical profiles, and thus, molecular targeting of these ubiquitin ligases, in particular, Pirh2, may have therapeutic value for human lung carcinomas.
|
28601655 |
2017 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Several novel findings were obtained: (i) cytoplasmic p27 was observed in 8.6%, most frequently in SCC (13.3%), and correlated with nodal metastasis (P=.0044), (ii) significant inverse correlation between nuclear p27 and Pirh2 expression was observed by statistical analysis and at the cellular level, and (iii) cytoplasmic Pirh2 and total (cytoplasmic and/or nuclear) Pirh2 were significantly correlated with the nodal status (P=.0225, 0.0314), the pathological stage (P=.0213, 0.0475) and recurrence-free survival (P=.0194, 0.0482, respectively) in AC.
|
28601655 |
2017 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Decrease of PIRH2 expression in the breast cancer cell line MDA-MB-231 resulted in reduced tumor cell growth via the inhibition of cell proliferation and the interruption of cell cycle transition.
|
27393961 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Pirh2 protein expression was negative in most normal renal tissue specimens (23/30) but positive in 52.2% (48/92) of ccRCC specimens (P = 0.006).
|
23102595 |
2013 |
|
Malignant neoplasm of kidney
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Pirh2 mRNA overexpression correlated with high stage and grade of the renal cancer (P < 0.001 and P < 0.001 respectively).
|
23102595 |
2013 |
|
Renal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Pirh2 mRNA overexpression correlated with high stage and grade of the renal cancer (P < 0.001 and P < 0.001 respectively).
|
23102595 |
2013 |
|
Plasmacytosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Pirh2 mutant mice display elevated levels of c-Myc and are predisposed for plasma cell hyperplasia and tumorigenesis.
|
22125490 |
2011 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, 83.3% of HNSCC with lower p27 expression (labeling index < 20%) displayed high Pirh2 levels.
|
19445020 |
2009 |
|
Prostatic Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
|
16914734 |
2006 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, overexpression of hPIRH2 protein was detected in 73 of 82 (89%) resected prostate cancers, with a strong correlation between increased hPIRH2 expression and aggressive disease, as signified by high Gleason sum scores and the presence of metastatic disease (P = <0.0001 and 0.0004, respectively).
|
16914734 |
2006 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
|
16914734 |
2006 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Several novel findings were obtained: (i) cytoplasmic p27 was observed in 8.6%, most frequently in SCC (13.3%), and correlated with nodal metastasis (P=.0044), (ii) significant inverse correlation between nuclear p27 and Pirh2 expression was observed by statistical analysis and at the cellular level, and (iii) cytoplasmic Pirh2 and total (cytoplasmic and/or nuclear) Pirh2 were significantly correlated with the nodal status (P=.0225, 0.0314), the pathological stage (P=.0213, 0.0475) and recurrence-free survival (P=.0194, 0.0482, respectively) in AC.
|
28601655 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Decrease of PIRH2 expression in the breast cancer cell line MDA-MB-231 resulted in reduced tumor cell growth via the inhibition of cell proliferation and the interruption of cell cycle transition.
|
27393961 |
2016 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
However, the molecular mechanism of Pirh2 activation in tumorigenesis still remains poorly understood.
|
22570270 |
2012 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of Pirh2 is frequently detected in many clinical tumor tissues including hepatocellular carcinoma (HCC).
|
22570270 |
2012 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We also report that low expression of human PIRH2 in lung, ovarian, and breast cancers correlates with decreased patients' survival.
|
22125490 |
2011 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Consistent with the role p53 plays in suppressing c-Myc-induced oncogenesis, its deficiency exacerbates tumorigenesis of Pirh2(-/-) mice.
|
22125490 |
2011 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
A low level of expression of hPirh2 was found both at transcriptional and translational level in human hepatocellular carcinoma (HCC) when compared to non-cancerous tissue.
|
20452352 |
2010 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, overexpression of hPIRH2 protein was detected in 73 of 82 (89%) resected prostate cancers, with a strong correlation between increased hPIRH2 expression and aggressive disease, as signified by high Gleason sum scores and the presence of metastatic disease (P = <0.0001 and 0.0004, respectively).
|
16914734 |
2006 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Decrease of PIRH2 expression in the breast cancer cell line MDA-MB-231 resulted in reduced tumor cell growth via the inhibition of cell proliferation and the interruption of cell cycle transition.
|
27393961 |
2016 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Pirh2 protein expression correlated with tumor grade and stage (P < 0.001 and P < 0.001 respectively).
|
23102595 |
2013 |